Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

The author writes "In the realm of insurance coverage litigation, whether two or more claims filed in different time periods ...

The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Princeton-based qordata has appointed Michael T. O’Connor as its new CEO. With a distinguished career at the intersection of ...

Alexion is to make major cuts to its broad R&D pipeline and sever ties with partners as its CEO seeks to streamline the company's strategy. Lud­wig Hantson was appointed in March after the rare ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

Maryland’s life sciences industry is at the forefront of bringing life-saving medical advancements to market, improving the ...

Competing interests WKS received speaker’s fees from AstraZeneca, is an advisory board member and received speaker’s fees of Abbott, received research funding from Alexion Pharmaceuticals, Boehringer ...

Highlights The Delaware Supreme Court took a broad view of relatedness, holding that an SEC investigation and later class ...